Method for treating blood clotting factor inhibitors
AssigneeBaxter Travenol Laboratories, Inc.
InventorWilliam R. Thomas
Life of this patent
Estimating the term…
Abstract
Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa, about from 8-80; total factor IX, about from 15-112; factor IX precursor, 0 to about 30; factor X, about from 1-30; and factor Xa, about from 1-10 are used in therapeutically effective amounts to treat blood clotting factor inhibitors.
Claims5
A method for treating a patient having an inhibitor of a blood clotting factor, which comprises administering to the patient a therapeutically effective dose of an aqueous composition including, in units/ml, factor VIII correctional activity, about from 2-35;
- prothrombin, about from 1-10;
- thrombin, less than about 0.003;
- factor VII, about from 37-190;
- factor VIIa, about from 8-80;
- factor IX, about from 15-112;
- factor IX precursor, 0 to about 30;
- factor X, about from 1-30;
- and factor Xa, about from 1-10.
Dependencies are inferred from the claim text.